Xanthine oxidoreductase-IN-4

Name: Xanthine oxidoreductase-IN-4
Brand: MedChemExpress
SKU: HY-151974
Rating: 4.5 (0 reviews)

Cat. No.: HY-151974: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor. Xanthine oxidoreductase-IN-4 has inhibitory activity against XOR with an IC₅₀ value of 29.3 nM. Xanthine oxidoreductase-IN-4 can be used for the research of hyperuricemia.

Para uso exclusivo en investigación. No vendemos a pacientes.

Xanthine oxidoreductase-IN-4 Estructura química

No. CAS : 1026587-58-5

Tamaño	Stock	Cantidad
1 mg	Obtener un presupuesto 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
5 mg	Obtener un presupuesto 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Obtener un presupuesto 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
25 mg	Obtener un presupuesto 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 mg	Obtener un presupuesto 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 mg	Obtener un presupuesto
200 mg	Obtener un presupuesto

Synthetic products have potential research and development risk.

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

IC₅₀ & Target

IC50: 29.3 nM (XOR)^[1]

In Vitro

Xanthine oxidoreductase-IN-4 (Compound IIIc) has inhibitory activity against XOR with an IC₅₀ value of 29.3 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Xanthine oxidoreductase-IN-4 (Compound IIIc) (oral; 5 mg/kg) shows a significant hypouricemia effect in a potassium oxazinate/hypoxanthine-induced model of acute hyperuricemia^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice acute hyperuricemia model^[1]
Dosage:	5 mg/kg
Administration:	Oral
Result:	Reduced serum levels of uric acid significantly from 4 h after administration.

Peso molecular

309.32

Fòrmula

C₁₆H₁₅N₅O₂

No. CAS

1026587-58-5

SMILES

CCOC1=CC=C(C=C1)NC(C2=CC=C(C=C2)C3=NN=NN3)=O

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. Wen Peng, et al. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors. Eur J Med Chem. 2022 Nov 28;246:114947. [Content Brief]